Member Info for Badsterman

Unusual time to tweet , on a Sunday evening (or afternoon, if US time)?

Maybe news tomorrow?

VAL 201 mentioned in a stateside market research report, alongside some very big players.

Source;

https://thetalkingdemocrat.com/uncategorized/205737/global-tyrosine-protein-kinase-fyn-market-report-growth-insight-deep-research-segment-analysis-ab-science-sa-valirx-plc-astrazeneca-plc-bristol-myers-squibb-co-zen-bio-inc/

The major players covered in Tyrosine Protein Kinase Fyn Markets:

AB Science SA
ValiRx Plc
AstraZeneca Plc
Bristol-Myers Squibb Co
Zen-Bio Inc

Tyrosine Protein Kinase Fyn Market Breakdown by Type:

Dasatinib
Masitinib
VAL-201

OB,

Val feels special, doesn't it?

Suzy's terrific, however she's so transparent, almost to the point of naivety. I worry that she lacks the pharma business nous, but that's what Kevin Cox is there for.

SNG feels so close, the job hires, Ashfield deal, interferon science and US Activ support all point to a winner.

See you in the Bentley garage ;-)

Ohhh £2.36...that'll be a few pints OB, especially if SNG booms on P3 results, eh?

Great analytical posts by Rhubarb this week, provided an industry insiders insight into Suzy' strategy.

I'm still sweating on the deal though.

Thumbs up ;-)

Both molnupiravir and paxlovid have been lauded by the UK media as game changers.

I wonder if mainstream news will bother reporting this trial failure?

Nope, I thought not.

Great find Star and I love your enthusiasm,

However, world domination of the fried chicken market is extremely ambitious!!

Keep up the good work ;-)

Apologies,

I intended to include the fact that 12 New Fetter Lane is TekCapital's registered UK address.

Snippet from Companies House,

Smart Food Tek registered office address changed from Acre House 11-15 William Road London NW1 3ER England to 12 New Fetter Lane London EC4A 1JP on 2 December 2021

Maybe something is afoot.

Spurs,

Having purchased the majority of my holding at 1.91p, I actually quite like the clothes they have been wearing.

However, if Sareum wish to become more fashionable, that's fine by me.

Bruce,

I'll stand corrected.

I understood nosism as "the practice of using "we" in giving one's opinions"

I'm trying to wind up NDN71 and fill out parking tickets, both at the same time ;-)

NDN71,

I don't like your royal "we", it's a nosism (look it up)

Why don't you say "NDN71 deserves an update", instead of "WE deserve an update"

Synairgen have only ever released market sensitive information via an RNS.

What makes you think they'll change company policy because you "deserve it" or because "it's "reasonable"?

Yet again, what utter banal tosh you post.

NDN71,

You accuse others of posting banal tosh, then state - "we deserve an update from the company"

The company is under NO obligation to release updates keeping shareholders "informed", neither have the done so previously.

Please stop your "banal tosh".

Polygon crossed the threshold yesterday (3/2).

So that doesn't explain today's drop despite buys outweighing sells.

Seems to suggest someone is still accumulating.

Just took me 10 mins to top-up @1.787 on ii

Only a few grand too.

Valirx are doing absolutely fine, Suzy Dilly has taken over and is developing a promising legacy pipeline, plus some new collaborations.

If the same situation were replicated at Sareum (i.e. a change in leadership, commercial partnerships and a resulting share price increase) I'd be more than happy.

Got my vote too,

Anything that makes us more attractive to external investors and institutions has to be a good thing.

Expecting a dip this morning, which will be a buying opportunity for me.

Manifesto,

I've tweeted @Synairgenplc, so let's hope they pick up on it.

;-)

If you are worried about short term price dips just read the NIAID report and digest this...

"One existing program through which NIAID will develop safe and effective antivirals is the Antiviral Program for Pandemics (APP). The APP will focus on antivirals that directly act against viral targets, specifically for RNA viruses. Antivirals of interest will have broad use in the outpatient setting, reducing viral burden in the early stages of infection"

"NIAID will support the development and clinical evaluation of short-term, but broadly protective strategies including the use of inhaled or systemic immunomodulators."

Sound familiar?

Good find Ducati,

The NIAID report uses one of my favourite Marsdenism's - "broad spectrum".

;-)

What annoys me is the 10.26% spread (at time of posting)

It doesn't encourage any PI's to invest, I wonder why?